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Abstract
Our previous work shows that the stem cell factor SALL4 plays a central role in embryonic and leukemic stem cells. In this
study, we report that SALL4 expression was higher in drug resistant primary acute myeloid leukemic patients than those
from drug-responsive cases. In addition, while overexpression of SALL4 led to drug resistance in cell lines, cells with
decreased SALL4 expression were more sensitive to drug treatments than the parental cells. This led to our investigation of
the implication of SALL4 in drug resistance and its role in side population (SP) cancer stem cells. SALL4 expression was
higher in SP cells compared to non-SP cells by 2–4 fold in various malignant hematopoietic cell lines. Knocking down of
SALL4 in isolated SP cells resulted in a reduction of SP cells, indicating that SALL4 is required for their self-renewal. The SP
phenotype is known to be mediated by members of the ATP-binding cassette (ABC) drug transport protein family, such as
ABCG2 and ABCA3. Using chromatin-immunoprecipitation (ChIP), quantitative reverse transcription polymerase chain
reaction (qRT-PCR) and electrophoretic mobility shift assay(EMSA), we demonstrated that SALL4 was able to bind to the
promoter region of ABCA3 and activate its expression while regulating the expression of ABCG2 indirectly. Furthermore,
SALL4 expression was positively correlated to those of ABCG2 and ABCA3 in primary leukemic patient samples. Taken
together, our results suggest a novel role for SALL4 in drug sensitivity, at least in part through the maintenance of SP cells,
and therefore may be responsible for drug-resistance in leukemia. We are the first to demonstrate a direct link between
stem cell factor SALL4, SP and drug resistance in leukemia.
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Introduction
Leukemic stem cells (LSCs) are cells that can give rise to
leukemia in transplant murine models, and therefore have self-
renewal property. It is hypothesized that these cells are not
targeted under current chemotherapy regimens and therefore may
account for drug resistance and leukemia relapse. Identifying
genes or signaling pathways involved in self-renewal of LSCs will
likely promote the development of more effective treatments for
leukemia and other cancers [1–4].
Several methods are currently being used to isolate and study
hematopoieticstemcells(HSCs)orLSCs,includingtheuseofHSCs
or LSCs cell surface markers [5–10] and the use of Hoechst 33342
dye efflux to identify side population (SP) [11–16] . There are
advantages and disadvantages to using either approach. Isolation of
HSCsorLSCs bycellsurfacemarkersisbettersuitedforsubsequent
functional studies such as in vivo transplantation since the Hoechst
dye is toxic to the cells and therefore might impair their
physiological functions. On the other hand, studying SP cells might
be a better approach to identify LSCs with potential resistance to
chemotherapeuticagents thatmayaccountforleukemicrecurrence.
As characterized by Goodell et al [17], SP from primary AML
patients not only has the ability to transfer leukemic phenotypes in
NOD-SCID mouse model, but more importantly, these cells have
the capacity for rapid efflux of anti-leukemic drugs such as
daunorubicin and mitoxantrone. Therefore, SP cells may be a
major target for leukemic remission. In addition to blood cells, the
SP approach has been used for enrichment for other cancer stem
cells, such as breast cancer stem cells [15].
Several ATP binding cassette (ABC) transporter genes have been
reported to be responsible for the SP phenotype. Currently, the ABC
family has 48 members, which is further divided into 7 subfamilies
based on similarities in protein structure, (ABCA, B, C, D, E, F and
G) [18] . Among these transporters are the breast cancer resistance
protein (BCRP or ABCG2) and ABCA3 [19,12,13,20–22].
ABCG2 is one of the earliest ABC transporters to be identified and
characterized. It is expressed in normal hematopoietic CD34+ cells
and has been associated with a subpopulation of tumor cells that
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additional ABC transporters are involved in drug resistance of SP
cells. ABCA3 is highly expressed in AML patient samples and its
expression is associated with unfavorable clinical treatment outcome
[23]. Furthermore, the expression of ABCA3 is enriched in leukemic
SP cells and has been linked to multidrug resistance by facilitating
lysosomal sequestration of drugs in AML primary cells and cell lines
[23,24,14,15,20].
Previously, we have shown that SALL4, a zinc finger
transcription factor, forms a core transcriptional network with
Oct4, Nanog and Sox2, which governs the self-renewal property of
murine embryonic stem (ES) cells [25,26]. In addition, we found
that during normal hematopoiesis, SALL4 is preferentially
expressed in human CD34+ hematopoietic stem/progenitors
(HS/PCs) and down-regulated in CD34- cells during hematopoi-
etic differentiation [27]. Furthermore, SALL4 is aberrantly
expressed in human acute myeloid leukemia, and transgenic
SALL4 mice develop acute myeloid leukemia [27]. Loss-of-
function studies have demonstrated that SALL4 is a key regulator
in leukemic cell survival and down-regulation of SALL4 led to
significant apoptosis of leukemic cells [28]. The important role of
SALL4 in normal HSC and leukemic stem or initiating cells is
supported by its interactions with several key players in self-
renewal of HSCs and LSCs: Wnt/b-catenin [27], Bmi-1 [28,29],
and PTEN [30].
In this study, we reported that SALL4 expression was higher in
drug resistant primary acute myeloid leukemic patients than those
from drug-responsive cases. In addition, while overexpression of
SALL4 led to drug resistance in cell lines, cells with decreased
SALL4 expression were more sensitive to drug treatments than the
parental cells. Having observed that SALL4 was enriched in HS/
PCs that were identified by cell surface markers, we planned to
evaluate the expression of this stem cell factor in SP and non-SP
cells in various blood cancer cell lines (HL-60, NB4, KG1a and
RPMI8226 cells), as well as investigate the role of SALL4 in drug
resistance and cancer stem cells as identified by SP studies. We
found that SALL4 expression was enriched in the SP when
compared to the non-SP counterpart. We also found that SALL4
could promote the expression of the ABC transporter genes, such
as ABCA3 and ABCG2, and knocking down of SALL4 expression
led to a decreased SP. These observations suggest that SALL4 can
contribute to the SP phenotype by regulating the expression of
ABCA3 and ABCG2. Therefore, by targeting SALL4, we may be
able to target the leukemic SP or LSC population.
Materials and Methods
Flow cytometry analyses
For side population studies, the cells (1610
6/ml) were incubated
at 37uC for 90 min with 5 mg/ml Hoechst 33342 (Invitrogen),
either alone or in the presence of 50 mM verapamil (Sigma) as a
negative control. Side population cells were analyzed on a flow
cytometer equipped with 424/444 nm band pass, 670 nm long
pass and optical filter. Dead cells were excluded by gating on
forward and side scatter which eliminated the PI-positive
population. The data were analyzed by FlowJo (Ashland, OR,
USA). Freshly sorted SP cells were counted, plated in six-well
plates, and cultured with RPMI1640 for 7–8 days. Expanded SP
cells were transduced with retrovirus for knocking down of SALL4
and reanalyzed for side population as described below.
Cell lines and cell culture
All cell cultures were maintained at 37uC with 5% CO2. Several
human malignant hematopoietic cell lines, NB4, HL-60, KG1a,
RPMI8226, 293(embroyonic kidney), MCF7 (breast cancer) and
HeLa cell lines were obtained from American Type Culture
Collection Inc (ATCC, Lawrenceville, GA, USA).
Human CD34+ cells
CD34+ cells were purified from primary human blood samples
obtained from Lonza Walkersville Inc (Maryland, USA). Briefly,
the samples were spun down at 2,400 rpm for 5 seconds at 4uC
and the supernatant was discarded, the pellet was then
resuspended in 1 mL of 16PBS supplemented with protease
inhibitor cocktail. The cells were then sorted using the EasySep
Human Whole Blood/Buffy Coat CD34 Positive Selection Kit
(Stemcell Technologies, Vancouver, Canada). 200 mL of the
EasySep CD34 antibody serum was added to the sample and
incubated at room temperature for 15 minutes, then 100 mL of the
EasySep magnetic bead mixture was added and incubated at room
temperature for 10 minutes. 3 mL of the sample was selected in a
12675 mm round-bottom polystyrene tube (BD Falcon, San Jose,
CA) using ‘‘The Big Easy’’ EasySep Magnet (Stemcell Technol-
ogies). Selection occurred when the sample in the tube was
incubated in the magnet at room temperature for 5 minutes, and
then the supernatant was discarded. The remaining sample was
washed three times with 1.5 mL of 16PBS supplemented with 2%
FBS and 1 mM EDTA, each with a 5 minute incubation period in
the magnet between discarding of the supernatant.
ChIP (Chromatin immunoprecipitation)
293 cells were transiently transfected either with a full length
SALL4A, SALL4B or an empty vector. Cells were cross-linked, lysed,
and sonicated. Chromatin immunoprecipitations were conducted
with a polyclonal anti-SALL4 antibody as described before [28,29],
followed by quantitative real-time PCR. Three sets of ABCA3 and
two sets of ABCG2 primers were used to validate the pulldown DNA
fragments. Fold enrichment was calculated after normalization with
input (no antibody added) of transfected cells. The ABCG2 primers
for PCR were 59- CCTGGATGTCCGGGTCTC-39 (forward-1),
59-AACCTTTTGAGTGGGCACAG-39 (reverse-1), 59-CTGTG-
GAGGAACTGGGTAGG-39 (forward-2), 5-CAAAGGCTCAG-
GATCTCAGG-39 (reverse-2) and for ABCA3 was 59-TCTGGG-
ACGAAGCAGAGAAT-39 (Positive forward), and 59- TGAGCA-
TACAGGGGGAAAA-39 (Positive reverse). 59-TCTGAGTCAGC-
CAGTTCTGGTA-39(Negative1-forward), 59-CACCCGGTCAT-
ATCCTCAGT-39(Negative1-reverse), 59-TTTGGCATTTATGT-
GTCAGGT-39(Negative2-forward), 59-TGAGTCTCAATTTCC-
TATCCCTAAA-39(Negative2-reverse).
Quantitative real-time PCR (qPCR)
Pulldown DNA from ChIP was measured by UV spectropho-
tometry. About 60 ng of DNA was utilized to perform qPCR with
iTaq SYBR Green Supermix (Bio-Rad). Reactions were carried
out in duplicates.
Quantitative real-time RT-PCR (qRT-PCR)
Total RNA was extracted with Trizol reagent (Invitrogen) or
RNeasy Micro Kit (Qiagen) according to manufacturer’s instruc-
tions, and the concentration was measured by UV spectrophotom-
etry. 100 ng of total RNA was applied to conduct qRT-PCR by
using iScript One-Step RT-PCR Kit with SYBR Green (Bio-Rad).
The average threshold cycle for each gene was determined from
duplicate reactions and the expression level was normalized to
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). SALL4
primers (amplicon length, 68 bp) were the following: 59- TGCAG-
CAGTTGGTGGAGAAC -39 (forward); 59-TCGGTGGCAAAT-
SALL4 Affects the Side Population
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length, 120 bp): 59- TGTACGCCAACACAGTGCTG -39 (for-
ward); 59- TCAGGAGGAGCAATGATCTTG -3 (reverse).
ABCA3: 59-CTCCGAGAAGGACTTTGAGG-39 (forward); 59-
TCCGTGTGTAACTGAACCGT-39 (reverse), and ABCG2; 59-
CCCAGGCCTCTATAGCTCAG-39 (forward); 59-CGTCAG-
GAAGAAGAGAACCC-39 (reverse). The expression levels of
SALL4 in AML patients were analyzed by 2-DDCt relative
quantitative method.
Retrovirus production and SALL4 knock-down
The specificity of the SALL4 shRNA has been described in our
previous publications [28,31]. Briefly, three short-hairpin RNA-
expressing plasmids, one control (GFP-pRS) and two SALL4
specific (no. 7410, no. 7412; all 3 from Origene, Rockville, MD),
were transfected into Phoenix packaging cells (Orbigen, San
Diego, CA) using Lipofectamine 2000 (Invitrogen, Frederick,
MD). Virus was harvested 48 hours after transfection and filtered
through a 0.45-mm filter. Virus supernatant was added to KG1a or
CD34+ cells with 8 mg/ml polybrene. Cells were centrifuged at
2506 g for 2 hr and incubated for 90 min. After 90 min of
incubation, virus supernatant was replaced with fresh medium and
incubated for 24 hr.
MTT assay and drug treatment
2000 cells were seeded into 96-well plates in RPMI 1640
containing 10% FBS. After 20–24 hr, cells were replenished with
fresh complete medium containing either a test compound or H2O
as a vehicle. At the indicated time, the cell proliferation reagent
MTS-1 (Promega) was added to each well. The assay was
measured at 450 nm using an ELISA Reader (Millipore).
Patient Study Population
Ethics Statement. Discarded peripheral blood samples were
obtained from 68 AML patients (AML M2: 42; AML M3: 12;
AML M4: 5, AML unclassified: 9) and 30 healthy individuals,
between December 2007 and May 2008, in the Peking Union
Medical College Hospital, under an approved protocol from the
IRB of Peking Union Medical College Hospital. Informed consent
was not obtained due to the discarded nature of these samples and
the data were analyzed anonymously.
The diagnosis was based on standard cytological criteria
according to the French–American–British (FAB) classification
[32]. Patient diagnosis was sub-classified by morphology and by
immunophenotyping by two independent pathologists. Patient age
at diagnosis ranged from 18 to 82 years with a median of 44 years.
The AML patients were given standard chemotherapy with most
of them responding to the treatments. Ages of the healthy
individuals ranged from 14 to 65 years with a median of 41 years.
The 461-AML-cohort was downloaded from Gene Expression
Omnibus dataset GSE6891. The data was then analyzed using
ParteK Genomic Suite (Missouri, MO, USA). The mean intensity
of SALL4 was calculated for the dataset, and each sample was
then stratified as SALL4 high or SALL4 low according to their
SALL4 expression value.
Statistical Analysis
SPSS software (version 11.0, SPSS Inc.) was used for statistical
analysis of SALL4 expression. All results were presented as a
median value (quartile 1, quartile 3) because the SALL4
expression in leukemia showed a skewed distribution. Using the
Mann-Whitney test, we compared the SALL4 expression between
AML in different treatment stages and the healthy control,
between pre-treatment and post-treatment AML patients. The
Pearson correlation coefficient between SALL4 expression and
AML treatment and status was determined. In all cases, a P value
,0.05 was considered statistically significant. Statistic comparisons
of the ABC genes in SALL4 high- or SALL4 low- group were
made using student t-test.
Electrophoretic Mobility Shift Assays (EMSAs)
DNA-protein binding assays were carried out with nuclear
extract from SALL4B transfected HeLa cells prepared with Nuclear
Extract kit (Active Motif) according to manufacturer’s instructions.
Synthetic complementary oligonucleotides were 39-biotinylated
using the biotin 39-end DNA labeling kit (Pierce) according to the
manufacturer’s instructions. The sequences of the oligonucleotides
used are 59- GCAGAGAATGGGGAAGACATTTTGGATGG-
GGTGTTGCAG-39 (#1), 59- TCTGTGAAGACTGATGGG-
GAAAGGGGGTTTTTAGGATGTT-39 (#2) and 59-AAGTCA-
GAGCGCCCTCTGCCGGGCATGGGCAGCATGCAGG-39
(#3) for ABCA3. Binding reactions were carried out for 20 min at
room temperature in the presence of 50 ng/ml poly (dI-dC), 0.05%
Nonidet P-40, 10 mm EDTA, and 2.5% glycerol in 16 binding
buffer (LightShiftTM chemiluminescent EMSA kit, Pierce) using
20 fmol of biotin-end-labeled target DNA and 2 mgo fn u c l e a r
extract. Unlabeled target DNA (4 pmol) or 2 ml of anti-SALL4
antibody [28] or anti-Tubulin antibody (Sigma) was added per 20 ml
of binding reaction as indicated. Assays were loaded onto native 6%
polyacrylamide gels pre-electrophoresed for 60 min in 0.56 Tris
borate/EDTA and electrophoresed at 100 V before being trans-
ferred onto a positively charged nylon membrane (HybondTM-N+)
in0.56Tris borate/EDTA at 100 V for 30 min. Transferred DNAs
were cross-linked to the membrane at 120 mJ/cm2 and detected
using horseradish peroxidase-conjugated streptavidin (LightShiftTM
chemiluminescent EMSA kit) according to the manufacturer’s
instructions. Additional method is listed Text S1.
Results
SALL4 expression is associated with AML treatment
status
We have shown that SALL4 is aberrantly expressed in AML
patients [33,27]. In this study, we sought to investigate whether
SALL4 expression level is associated with AML treatment status.
Usingthe optimizedqRT-PCRconditionthatweestablishedearlier
[33,27,28], we compared SALL4 expression level in AML patients
withouttreatment (N=36), AMLpatients inthe complete remission
(CR) phase (N=25), AML patients in the partial remission (PR)
phase (N=7), and healthy controls (N=30). The definition of CR
or PR is based on blast count after the completion of standard
chemotherapy. The blast count in bone marrow of the patients in
AML CR phase was #5%, the blast count in bone marrow with the
patient in AML PR phase was between .5% and #20%.
We noticed that SALL4 had the highest expression level in
acute AML patients without treatment [69.01 (range:
17.20,120.28)], low expression level in PR patients [4.18 (range:
1.76,5.04)], even lower expression level in CR patients [1.82
(range: 0.50,2.96)], and the lowest expression level in healthy
controls [0. 80 (range: 0.35,1.13)]. The median level of SALL4
mRNA expression in patients with acute AML without treatment
was 86-fold higher than that in the healthy controls (Z=26.89,
p=0.001), 38-fold higher than that in the AML CR phase
(Z=26.34, p=0.001), and 17-fold higher than that in the PR
phase (Z=23.61, p=0.001). The level of SALL4 expression in
the AML PR phase was 2-fold higher than that in the AML CR
phase (Z=22.44, p=0.015, Figure 1A).
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changes of SALL4 expression during the course of AML treatment
at three time points, which included the untreated acute phase, the
improving phase (whereby the patient was responding to the
chemotherapy as indicated by decreased blast counts, and was at
the mid-point of their treatment cycles), and the end of the
treatment cycle (of eight patients, five in complete remission (CR)
phase, and the other three were in relapse phase). The level of
SALL4 expression declined throughout the treatment process for
the drug responsive group (Figure 1B) and increased in the drug-
resistant group (Figure 1C).
Overexpression of SALL4 is associated with drug
resistance in cell lines
To assess whether the increased expression of SALL4 in AML
relapse patients is the consequence or the cause of drug resistance
in AML, we compared the proliferation state of a stable cell line
with SALL4 overexpression to that of the controls after exposure
to two clinically common active chemotherapy agents: doxorubi-
cin and daunorubicin.
To determine the effect of SALL4 in drug resistance, we choose
to use 293 cells for the following reasons. First, since SALL4 is
expressed in solid tumors such as germ cell tumors (GCTs), gastric
cancer, and breast cancer [34,35] in addition to AML, we
hypothesized that SALL4 can confer a general drug resistant
phenotype. Second, the 293 cells have relatively lower SALL4
expression compared to blood cell lines, which is better to
demonstrate the gain-of functional study. 293 cells overexpressing
SALL4B or vector control were plated in a 96-well plate and
treated with various concentrations of doxorubicin or daunorubi-
cin. At 48 hours after drug treatment, cell proliferation was
measured using the MTS reagent (Promega). Similar to their
clinical activity, both agents significantly inhibited the proliferation
of 293 cells. As shown in Figure 2A and B, overexpression of
SALL4 resulted in a significant reduction in cytotoxicity observed
following exposure to doxorubicin (2.0-fold) and daunorubicin
(1.5-fold). We next performed the loss-of-function analysis of
SALL4. Knocking down of SALL4 in a myeloid leukemic line,
KG1a cells, was achieved by retrovirus-mediated delivery of
shRNA against SALL4 as we previously described [28,31]. qRT-
PCR analysis showed that retroviral infection markedly repressed
SALL4 expression in KG1a cells by 60%. As shown in Figure 2C,
SALL4 knock-down cells displayed more sensitivity to doxorubicin
than parental cells. These data suggest that SALL4 plays an
important role in drug sensitivity.
Preferential Expression of SALL4 in the SP cells
SP cells are defined as cells that show higher efflux of chemicals
including DNA-binding dye Hoechst 33342. Therefore, it is not
surprising that SP cells are resistant to multiple chemotherapy
drugs. Since increased SALL4 expression is associated with drug
resistance, we hypothesized that SALL4 might mediate drug
resistance at least in part, through the maintenance of SP cells. We
first examined the endogenous expression level of SALL4 in SP
cells in several hematological cell lines. The SP, as defined by low
Hoechst 33342 blue/red fluorescence intensity after incubation
with Hoechst 33342, was detected in all cell lines tested at a
frequency of 0.5–5%. As a control, this side population
disappeared after treatment with verapamil (50 mM) which
inhibited the function of the ABC transporter (Figure 3A, right
panel). A representative SP profile from KG1a cell line is shown in
Figure 3A. We then sorted SP and non-SP cells from four different
blood cancer cell lines, HL-60, RPMI8226, NB-4 and KG1a cells,
and measured the expression of SALL4 in SP cells and non-SP
Figure 1. SALL4 expression in AML patients correlated with
treatment status. SALL4 had the highest expression level in acute
untreated AML patients (N=36), low expression level in partial
remission (PR) patients (N=7), lower expression level in complete
remission (CR) patients (N=25) and healthy controls (N=30) (A). The
level of SALL4 expression declined at remission phase after chemo-
therapy with decreased blast count in five AML patients in the CR group
(B, n=5), but increased in the PR group with drug resistance (C, n=3).
Each line represents one patient. Y axis: relative SALL4 expression level
reported as 2-
DDCt relative quantitative method.
doi:10.1371/journal.pone.0018372.g001
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3.0-, 2.2- and 3.0-fold higher in HL-60, RPMI8226, NB-4 and
KG1a SP cells than those from the corresponding non-SP cells,
respectively (Figure 3B). Furthermore, SALL4 protein expression
was investigated in SP and Non-SP cells by an immunofluorescent
stain in KG1a cell line. Consistent with the RNA results, SALL4
was more abundantly expressed in SP cells compared to non-SP
KG1a cells (Figure S1). These data suggest that SALL4 is more
abundant in SP cells compared to non-SP cells.
Knocking-down of SALL4 leads to reduced frequency of
the side population
To determine if SALL4 is necessary for SP cell maintenance,
we next performed loss-of-function study of SALL4 in side
population. We first sorted SP cells from KG1a cells. Due to the
low number of SP cells, we cultured the sorted SP cells with
media containing 10% FBS and expanded them for a week. The
SP cells could give rise to both SP and non-SP cells during this
culture system, a character that is only observed in SP cells. On
the other hand, culture of the non-SP cells yielded no non-SP
cells (Figure S2). In addition, in vivo transplantation experiments
showed that the KG1a SP population had an increased leukemic
engraftment when compared to that of the non-SP cells in a
xenotransplant mouse model. Four months after injection of
1610
5 of SP or non-SP cells into sub-lethally irradiated NOD-
SCID mice, the SP recipients had 37% human CD45 cells
detected in their bone marrows that were derived from the SP
cells, while the non-SP recipients had only 0.1% human CD45
cells (Figure S3). In summary, these features suggest that the SP
cells that we sorted from the KG1a cell line are enriched for
leukemic stem cell properties and are consistent with other
reports. The expanded SP cells were then infected with
retroviruses containing shRNA against SALL4 or control
scramble shRNA using the same approach as described
previously [28]. The SP cell quantification was re-analyzed.
qRT-PCR analysis showed that SALL4 expression was reduced
by 40%. SALL4 knock-down significantly decreased the percent-
age of the SP cells from 1.31%to 0.36%. These data suggest that
SALL4 plays an important role in the maintenance of side
population (Figure S4).
Figure 2. Effects of SALL4 on drug sensitivity. Overexpression of SALL4 resulted in more resistance to doxorubicin (A) and daunorubicin (B)
compared to control cells. 293 cells overexpressing SALL4B (filled circles) or an empty vector (open circles) were seeded in a 96-well plate and
cultured with various concentrations of doxorubicin (A) or daunorubicin (B). At 48 hr after treatment, proliferation was measured with the MTS
reagent (Promega). (C) Retroviral-mediated SALL4-knockdown KG1a or control cells were treated with doxorubicin. At 24 hr after drug treatment, cell
proliferation was measured. Data is represented as mean 6 S.D. from three independent experiments. X axis: relative proliferation rate. Y axis:
concentrations of doxorubicin or daunorubicin.
doi:10.1371/journal.pone.0018372.g002
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ABCG2 gene in vivo
It was reported that the ATP binding cassette (ABC) transporters
can contribute to drug resistance. We have mapped SALL4 global
gene targets using chromatin-immunoprecipitation followed by
microarray hybridization (ChIP-on-chip) in myeloid leukemic NB4
cells [28], normal human CD34+ bone marrow cells, and 293 cells
(unpublished data). ABCA3, but not ABCG2, was identified as a
potential SALL4 downstream target gene in all three cell types. We
then sought to validate whether SALL4 could bind to the promoter
regions of ABCA3 but not ABCG2 quantitatively using regular
ChIP coupled with qPCR. Based on the global chip array results
withpotentialSALL4bindingsites,we designed 3 setsof primers for
the ABCA3 promoter region (one was from a peak region, two sets
were designed on non-peak regions for negative controls) and two
sets of primers for the ABCG2 promoter regions (Figure 4A).
293 cells were transfected with a control vector or SALL4B
construct. Total chromatin was isolated and fragmentized by
sonication. Chromatin containing SALL4 protein was immuno-
precipitated with a SALL4 antibody. To determine whether the
promoters of ABCA3 or ABCG2 could be co-immunoprecipitated
by the SALL4 complex, we performed PCR reactions to amplify
the promoter regions. A fragment of the ABCA3 promoter region
was detected in the SALL4 complex, in contrast, neither of the two
ABCG2 promoter regions was detected (Figure 4A). Similar data
was obtained using KG1a cells ((Figure S5). These data suggest
that SALL4 can bind to the ABCA3 promoter directly but
probably not to the ABCG2 promoter.
To determine a specific protein-DNA interaction between
SALL4 and the ABCA3 promoter, nuclear extracts from HeLa
cells overexpressing SALL4B (Figure 4B) were used in EMSA
assay. Based on our ChIP-qPCR result, we designed 3 probes
Figure 3. Relative expression of SALL4 in SP and non-SP cells from blood cancer cell lines. (A) Representation of FACS profile of SP cells
from KG1a. A SP cell profile in the presence of verapamil (50 mM) was at the right as a control. (B) qRT-PCR analysis of SALL4 in SP (dark bars) and non-
SP (open bars) cells from HL-60, RPMI8226, NB-4 and KG1a cells. For quantification of gene expression, amplification of GAPDH was performed as an
endogenous control to standardize the amount of sample. Shown here are the representative results of at least two independent experiments. Y axis:
relative SALL4 expression (fold) in comparison to non-SP.
doi:10.1371/journal.pone.0018372.g003
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PLoS ONE | www.plosone.org 6 April 2011 | Volume 6 | Issue 4 | e18372Figure 4. SALL4 binds to the promoter regions of ABCA3. (A) ChIP-qPCR showed that SALL4 could bind to ABCA3 but not ABCG2 promoter.
Antibody against SALL4 was used to immunoprecipitate DNA fragments from SALL4B-overexpressed 293 cells and fold enrichment was compared to
input after normalization with GAPDH. Three pairs of primers in the ABCA3promoter region(left panel) andtwopairs of primers in the ABCG2 promoter
region(rightpanel) wereused inChIP-qPCR analysis. TheABCA3promoter was foundtobe boundbySALL4B. (B), ForEMSA,Western blot analysis using
anti-SALL4 antibody was performed on whole cell lysate (left) or nuclear extract (right) from HeLa cells expressing SALL4B. (C), EMSA probes sequences
(underlined, bold) in the ABCA3 promoter region used for EMSA are indicated. EMSAs were performed to analyze the binding of proteins from nuclear
extract of SALL4B expressed HeLa cells to the ABCA3 promoter as described under ‘‘Materials and Methods’’. (D), EMSA using three different probes in
the ABCA3 promoter regions. Lane 1–3 are with probe #1, lane 4–6 are with probe #2, and lane 7–9 are with probe #3. Lane 1, 4 and 7 are probe-only
reactions, a 200-fold excess of unlabelled probes of each probe was added in lane 3, 6 and 9. (E), EMSA was performed with probe #1. Lane 1, labeled
oligonucleotide; lane 2, labeled oligonucleotide + nuclear extract; lane 3, labeled oligonucleotide + nuclear extract + 200-fold molar excess of unlabeled
oligonucleotides; lane 4, labeledoligonucleotide + nuclear extract + anti-SALL4 antibody;lane5,labeled oligonucleotide+ nuclear extract + anti-Tubulin
antibody. Rabbit IgG (lane 6) and mouse IgG (lane 7) were used as controls. Results denote mean 6 S.D. from two independent experiments. Y axis:
relative fold enrichment of ChIP-promoter region in SALL4B pull-downs when compared to that of input.
doi:10.1371/journal.pone.0018372.g004
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determined which probe could form complex with SALL4B
(Figure 4D). As shown in Figure 4D, probe #1 formed a strong
complex with SALL4B nuclear extract (lane 2), and the binding
was completely ablated with unlabelled oligonucleotide probe #1
(lane 3). In addition, this specific band was ablated after addition of
a SALL4 antibody (Figure 4E, lane 4), but not with addition of a
Tubulin antibody (Figure 4E, lane 5), IgG (Figure 4E, lane 6 and
7) was used as a negative control. The ablation of a specific band
has been reported when an antibody being added to a protein-
DNA interaction in an EMSA experiment, and is due to fact that
certain antibodies can compete or interrupt the protein-DNA
interaction. Though no supershift band was observed with our
SALL4 antibody, we interpreted the ablation of a specific band by
our SALL4 antibody but not the controls (IgG or Tubulin
antibodies) a consequence of competition or interruption of
SALL4 protein-DNA interaction by this antibody.
Transcriptional activation of ABCA3 gene by SALL4
We then sought to investigate whether SALL4 can regulate the
ABCA3 promoter by analyzing the human ABCA3 promoter
activity. A 59 upstream of the transcription start site of ABCA3,
which contained the SALL4 binding site, was subcloned into the
59 end of a pGL4.2 basic luciferase reporter plasmid (Figure S6).
The SALL4 responsiveness of the ABCA3 promoter was then
evaluated through cotransfection of the ABCA3-luciferase con-
struct and Renilla luciferase plasmid together with increasing
ratios of the SALL4A or SALL4B expression constructs relative to
the ABCA3 promoter construct. As we increased the molar excess
of the SALL4A or B constructs, the ABCA3 promoter was
activated in a dose-dependent manner (Figure S6).
SALL4 is able to affect the levels of endogenous
expressions of ABCA3 and ABCG2
To determine the regulation of ABCG2 and ABCA3 genes by
SALL4, we next examined the expression levels of these two genes
in 293 cells overexpressing SALL4A and SALL4B. 293 cells were
transiently transfected with SALL4A or SALL4B or pcDNA as a
control. At 48 hr after transfection, RNA was isolated from
transfected cells. By qRT-PCR, we found that the expression level
of ABCA3 in SALL4 overexpressing cells was increased by 33%
compared to those of the controls (Figure 5A). Surprisingly, the
expression of ABCG2 was increased even more, up to 74%.
We next measured the expressions of ABCA3 and ABCG2 in
SALL4-knockdown cells. qRT-PCR analysis showed that retrovi-
ral infection with shRNA for SALL4 markedly repressed SALL4
expression in CD34+ cells by 70% (Figure S7). Down-regulation of
SALL4 repressed the expression of ABCA3 gene by 80% in
CD34+ cells, and similarly, decreased expression level of ABCG2
was observed as well. Similar results were observed for KG1a cells
(Figure 5B and data not shown).
We further investigated the correlation of SALL4 and ABCA4
and ABCG2 expression in blood cell lines. SALL4 expression in
HL60 was relatively lower than that in KG1a and RPMI8226.
Similar to the expression of SALL4, the expression of ABCA3 and
ABCG2 was lower in HL60 and higher in KG1a and RPMI8226
cell lines (Figure 5C).
Having established the correlation of SALL4 and the ABC
genes in cell lines and CD34+ cells, we next investigated its clinical
association in primary AML patients. Using the AML cohort first
described by Roel et al [36], we stratified these 461 AML samples
into SALL4-high and SALL4-low, according to mean intensity of
SALL4. The expression of ABCA3 and ABCG2 was then
examined in these two groups. Interestingly, the expression of
both genes was significantly higher in the SALL4 high group
(P=0.0001, Figure 5D, and P=0.02 Figure 5E respectively)
compared to SALL4 low group, showing a positive correlation of
ABCA3 and ABCG2 with SALL4 in primary AML samples.
To validate, we performed real-time PCR on 34 primary
samples from a separate cohort. These samples were stratified with
the mean value of SALL4 to SALL4 high and SALL4 low groups.
It was found that ABCG and ABCA3 are significantly higher in
the SALL4 high population (P=0.001, P=0.0001 respectively),
and this correlates well with the Roel data set (Figure 5F and G).
Taken together, these results suggest that ABCA3 is a direct
downstream target gene of SALL4, and the expressions of two
ABC genes, ABCA3 and ABCG2, are positively regulated by
SALL4.
Discussion
The concept of cancer stem/initiating cells is designed to define
a cancer subpopulation that has the potential to propagate the
tumor and may be responsible for driving tumor development,
progression, metastasis and drug resistance or relapse. Xenograft
transplantations have been used to test the tumorigenic ability of
subsets of cancer cells in immune-compromised mice. It was
initially observed that only a very small percentage of tumor cells
with unique surface markers had this property, and the bulk of the
cells in the tumor lacked this capacity. With the availability of
more immune-compromised mouse strains, the spectrum of cancer
cells that has this tumorigenic ability has grown broader. In
addition, the drug resistance or relapse properties of these cancer
initiating cells have not been vigorously tested in this transplan-
tation model using cells isolated by surface markers. Parallel to this
approach, the ability of a subgroup of cells to efflux lipophilic
fluorescent Hoechst dyes to produce a characteristic side
population (SP) profile based on fluorescence-activated flow
cytometric analysis has proven valuable as a marker to identify
multipotent stem cells in a variety of tissues, including ES cells and
various adult stem cells and cancer stem/initiation cells.
Therefore, it is more reasonable to combine the transplantation
and side population assays to define the cancer initiating cells. The
best demonstrated tumor model is from the SP from acute myeloid
leukemia samples, which have been shown to have leukemogenic
properties in a xenotransplantation model, as well as being
resistant to drug treatment [12,17]. These data indicate that the
ability of malignant SP cells to expel anticancer drugs may directly
improve their survival and sustain their clonogenicity during
exposure to cytostatic drugs, allowing disease recurrence when
therapy is withdrawn.
The expressions of several ATP binding cassette (ABC)
transporters, including breast cancer resistance protein (BCRP
or ABCG2) and ABCA3, are thought to be responsible for
expulsion or sequestration of the cytotoxic drugs [23,24,12,13].
These genes are highly expressed in normal hematopoietic CD34+
stem/progenitor cells and SP cells in AML samples [12,13]. The
mechanism(s) involved in the regulation of the expressions of these
genes remain under investigation.
SALL4 is a newly discovered pluripotency stem cell factor in
murine ES cells. Our group has also shown that it is involved in
the self-renewal of leukemic initiation and hematopoietic stem/
progenitor cells (HSCs). It is a unique gene that has important
functional role(s) in maintaining all three types of stem cells, such
as ES cells, HSCs and LSCs. We have shown that SALL4 plays an
essential role in myeloid leukemogenesis. It is aberrantly expressed
in human primary acute myeloid leukemia [27]. Overexpression
of SALL4 in a murine model leads to myeloid leukemic
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cell lines triggers apoptosis [28].
In this study, we correlated the expression of SALL4 with
primary AML patient diagnosis and treatment status. We found
that AML patients who responded to the treatment had decreasing
SALL4 expression throughout the treatment course; while AML
patients with disease relapse or drug resistance had increasing
SALL4 expression that was correlated to the disease progression.
We furthered our study by investigating whether change of SALL4
expression affect chemoresistance (drug responses) of leukemic
cells. We found that increased SALL4 expression in leukemic
KG1a and 293 cells was associated with chemoresistance, and
conversely, knocking down of SALL4 led to a more sensitive
response to drug treatment. We then propose that SALL4, a stem
cell factor gene, is responsible for the SP phenotype and drug
resistance by regulating the ABC genes.
The expression of SALL4 in SP and non-SP cells was
investigated and we found that SALL4 was enriched in SP
leukemic cells. The preferential expression of SALL4 in SP cells is
not limited to the hematopoietic system. In addition to AML,
SALL4 has been reported to be expressed in solid tumors such as
germ cell tumors (GCTs), gastric cancer, and breast cancer
[34,35]. We have also observed the expression of SALL4 in breast
cancer as reported. Moreover, SALL4 is enriched in SP in breast
cancer cell line MCF7 along with ABCA3 and ABCG2, and
increased SALL4 expression led to an expansion of SP in MCF7
cells (Figure S8–10).
As part of a global SALL4 gene target investigation, we
performed ChIP-on-chip on the leukemic cell line NB4, 293 cells,
as well as primary CD34+ cells. In all three data sets, we found
that SALL4 had potential binding sites for one ABC gene,
ABCA3. We further demonstrated that SALL4 could bind to and
activate the promoter of ABCA3. Therefore, ABCA3 is a direct
target of SALL4. Interestingly, SALL4 could affect the expression
levels of both ABCA3 and ABCG2. While overexpression of
SALL4 led to increased ABCA3 and ABCG2 expression, knocking
down of SALL4 in CD34+ cells and KG1a resulted in decreased
expression of ABCA3 and ABCG2, as well as the frequency of SP
cells. Most importantly, the expression of SALL4 was positively
correlated to those of ABCG2 and ABCA3 in primary leukemic
patient samples.
Though there is no evidence to support that ABCG2 is a direct
target of SALL4, at least by our study of ChIP-qPCR around its
promoter region, it is possible that SALL4 can regulate the
expression of ABCG2 through some distal regions which were not
investigated by our current study. Alternatively, we have shown
that SALL4 represses PTEN expression through recruiting the
NuRD complex [30]. The PTEN and Akt pathway has recently
been implicated in maintaining the SP phenotype in glioma stem
cells and breast cancer stem cells [37,38], probably through
affecting the activity of ABCG2. It is possible that SALL4 affects
the expression of ABCG2 (BCRP) indirectly through its regulation
of PTEN.
In summary, we are the first to connect a stem cell factor with
ABC genes that are responsible for the side population property, a
property shared by various normal and cancer stem cells. While
the biological implication of SALL4 and ABC transporters in ES
cells and other tissue stem cells remain a great interest for further
investigation, in this study, we focused on the functional role of
SALL4 in the SP of leukemic cells. The side population has been
proposed to be a tumor population with intrinsic mechanisms for
cytostatic drug resistance that might provide clues for improved
therapeutic intervention. Our results suggest that SALL4 plays a
role in drug sensitivity, at least in part, through the regulation of
ABC genes and maintenance of SP cells, and may be responsible
for drug-resistance in leukemia. Further studies will determine
whether SALL4 is a novel therapeutic target for leukemic stem/
initiation cells in primary AML patients.
Supporting Information
Figure S1 SP cells has significantly higher SALL4
protein expression than that of Non-SP cell. (A) Sorted
Non-SP cells (upper panel) or SP cells (lower panel) from KG1a
cells were immunostained with SALL4 antibody (Green for Sall4,
Blue for DAPI). (B) SALL4 fluorescence signal per cell was
quantified using Image J software.
(TIF)
Figure S2 Non-SP cells do not give rise to SP cells. (A)
KG1a cells were incubated with Hoechst 33342 dye as previously
described and analyzed by flow cytometry. Non-SP cells were
sorted and cultured with RPMI1640 media for 3 days. (B)
Cultured Non-SP cells were re-analyzed by flow cytometry and no
SP population was identified.
(TIF)
Figure S3 Increased leukemic engraftment of KG1a SP
in vivo in a xenotransplant mouse model. Four months
after injection of 1610
5 of SP or non-SP cells into sub-lethally
irradiated NOD-SCID mice, the SP recipients had 37% of human
CD45 cells detected in their bone marrows which were derived
from the SP cells, while the non-SP recipients had only 0.1% of
human CD45 cells by FACS analysis. X axis: mouse CD45
expression, Y axis: human CD45 expression.
(TIF)
Figure S4 Knocking down of SALL4 leads to reduced
frequency of the side population. (A) Freshly sorted SP cells
from KG1a were counted, plated in six-well plates and cultured
with RPMI 1640 for a week. Expanded SP cells were transduced
with retrovirus expressing SALL4-specific shRNA for knocking
down of SALL4 (lower panel) or scramble shRNA as a control
(upper panel) and re-analyzed for side population as previously
Figure 5. SALL4 affects the levels of endogenous expression of ABCA3 and ABCG2. (A) 293 cells were transiently transfected with SALL4A
or SALL4B or pcDNA as a control. At 48 hr after transfection, RNA was isolated from transfected cells. Transfected cells were subjected to qRT-PCR to
measure the mRNA expressions of ABCA3 and ABCG2. The mRNA expressions of ABCA3 and ABCG2 were significantly increased by SALL4. Data are
represented as mean 6 S.D. from three independent experiments. *** denotes p,0.001, ** p,0.01, *p,0.05. (B) CD34+ cells were transduced
with retrovirus expressing shRNA against SALL4 and subjected to qRT-PCR analysis to measure the expression levels of ABCA3 and ABCG2. The
expression level of ABCA3 was reduced by 80% and the expression level of ABCG2 was reduced by 74% in CD34+ cells compared to those of the
controls. The mRNA level was normalized with the internal control GAPDH. (C) qRT-PCR analysis of SALL4A and B, ABCG2, and ABCA3 in HL-60, KG1a,
and RPMI8226 cells. For quantification of gene expression, amplification of GAPDH was performed as an endogenous control to standardize the
amount of sample. (D and E) SALL4 and ABC gene expressions were correlated in primary AML samples. 461 primary AML samples (GSE6891) were
stratified into SALL4 high and SALL4 low using the mean intensity of SALL4 as a threshold. (F and G) qRT-PCR was performed on 34 primary samples
with primers for SALL4, ABCG2 and ABCA3. Mean value of SALL4 was used to stratify the samples to SALL4 high or SALL4 low groups. Data are
represented as mean 6 S.D. from three independent experiments. Y axis: Relative SALL4 expression when compared to controls.
doi:10.1371/journal.pone.0018372.g005
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in SALL4knockdown cells on the lower pane. (B) qRT-PCR
analysis showed that SALL4 expression was reduced by 40% in
the SALL4 shRNA-treated SP KG1a cells when compared to that
of scramble control shRNA treated ones.
(TIF)
Figure S5 Endogenous SALL4 specifically binds to the
ABCA3 promoter revealed by ChIP assay. Using KG1a
cells, ChIP assay was performed by using two antibodies against
SALL4 (Sall4-(1): SantaCruz (EE30), (2):in-house antibody) or
mouse IgG as a negative control. Enriched chromatin was
analyzed by PCR and elctroporesed on agarose gel.
(TIF)
Figure S6 Activation of the promoter of ABCA3 by
SALL4. (A) Diagram of ABCA3-Luc construct which contained
the SALL4 binding site. (B) ABCA3-Luc construct was cotrans-
fected to HeLa or 293 (data not shown) cells with Renilla luciferase
plasmid and increasing ratios of either the SALL4A (gray bars) or
SALL4B (black bars) overexpressing constructs. pcDNA (white
bars) was used as a control. Data represent the mean of three
different experiments. X axis: relative luciferase activity (fold) after
overexpression of SALL4A or B in comparison to that of control
vector. Y axis: ratio of SALL4A or B construct to control.
(TIF)
Figure S7 Down-regulation of SALL4 in CD34+ cells.
CD34+ cells were transduced with retrovirus expressing shRNA
against SALL4 and subjected to qRT-PCR analysis to measure the
expression levels of SALL4 The expression level of SALL4 was
reduced by 70% mRNA level was normalized with the internal
control GAPDH (N=3).
(TIF)
Figure S8 SALL4 is preferentially expressed in SP cells
in breast cancer cell line MCF7. SALL4 protein is expressed
in human immature teratoma (II) and breast cancer patients (III
and IV). Strong nuclear staining of SALL4 was found in these
samples while the negative control (I) with only secondary
antibody done on a breast cancer sample showed no nuclear
staining at all. Magnification: 2006.
(TIF)
Figure S9 SALL4 is preferentially expressed in SP cells
in breast cancer cell line MCF7. SP population sorted using
the same approach we described for leukemic cell lines and is
illustrated in (A). SALL4 expression as evaluated by qRT-PCR
was over 10 fold enriched in SP cells when compared to non-SP
cells. Similar enrichment of expressions of ABCG2 and ABCA3
was also observed in the SP cells from MCF7. Y axis: relative
SALL4, or ABCG2, or ABCA3 expression (fold) in comparison to
non-SP.
(TIF)
Figure S10 Increased SALL4 expression led to expan-
sion of SP cells in MCF7 cells. Overexpression of SALL4B in
MCF7 cells increased the SP cells from 0.6% to 3.08% (lower
panel), while SP in the control vector treated cells remained
unchanged (upper panel).
(TIF)
Text S1 Supplemental Material.
(DOC)
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